50 completed. 50 Phase 1, 22 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 50 | Completed 50 |
| Phase 2 | 22 | Completed 22 |
Follow Small Cell Lung Cancer: new trials by email Literature Review of Small Cell Lung Cancer trials Research Report on Small Cell Lung Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of AL8326 in Healthy Subjects 14C-labeled AL8326 - Small Cell Lung Cancer, Solid Tumors | Phase 1 | Completed | Advenchen Laboratories Nanjing Ltd. | 6 | 2025-02-21 | 2025-08-20 |
| A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas RO7616789, Tocilizumab - Small Cell Lung Cancer, Neuroendocrine Carcinoma | Phase 1 | Completed | Hoffmann-La Roche | 41 | 2023-01-23 | 2025-03-10 |
| AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC) Tarlatamab, AMG 404 - Small Cell Lung Cancer | Phase 1 | Completed | Amgen | 23 | 2021-09-27 | 2025-09-29 |
| First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours AZD8701, Durvalumab - Clear Cell Renal Cell Cancer, Non-Small-Cell Lung Cancer | Phase 1 | Completed | AstraZeneca | 60 | 2020-08-18 | 2024-11-05 |
| IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer IMP4297(senaparib) - Advanced Solid Tumours, Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Impact Therapeutics, Inc. | 59 | 2020-08-07 | 2024-09-19 |
| A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer Fluzoparib, temozolomide, SHR-1316 - Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 25 | 2020-06-11 | 2025-06-29 |
| NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors NT-I7, pembrolizumab (KEYTRUDA®) - Any Advanced Solid Tumors, Triple Negative Breast Cancer | Phase 1 / Phase 2 | Completed | NeoImmuneTech | 215 | 2020-06-10 | 2026-03-09 |
| PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers PLX038, Rucaparib, Ondansetron - Small Cell Lung Cancer, Extra-Pulmonary Small Cell Carcinomas | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 10 | 2020-04-08 | 2026-08-26 |
| A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine - Malignancy, Non-hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | Cyteir Therapeutics, Inc. | 169 | 2019-10-09 | 2024-12-24 |
| A Study of SHR-1316 and Fluzoparib（SHR-3162） in Small Cell Lung Cancer Patients 1.Experimental: A (Part 1): Fluzoparib and SHR -1316, 2.Experimental: B (Part 1): Fluzoparib and SHR -1316, 3.Experimental: C (Part 2): Fluzoparib and SHR -1316 Expansion - Small Cell Lung Cancer | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 23 | 2019-09-17 | 2022-06-21 |
| A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer LY3295668 Erbumine - Small Cell Lung Cancer | Phase 1 | Completed | Eli Lilly and Company | 48 | 2019-07-16 | 2021-08-05 |
| A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) XmAb®23104, Yervoy® (ipilimumab) - Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma | Phase 1 | Completed | Xencor, Inc. | 198 | 2019-05-01 | 2024-07-05 |
| FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors FT500, Nivolumab, Pembrolizumab - Advanced Solid Tumors, Lymphoma | Phase 1 | Completed | Fate Therapeutics | 37 | 2019-02-15 | 2023-05-01 |
| A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer ABBV-011, Budigalimab - Small Cell Lung Cancer | Phase 1 | Completed | AbbVie | 132 | 2018-10-24 | 2024-02-09 |
| A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies INCAGN02390 - Cervical Cancer, Gastric Cancer | Phase 1 | Completed | Incyte Corporation | 40 | 2018-09-24 | 2021-11-15 |
| M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers M7824, Topotecan, Temozolomide - Carcinoma, Small Cell, Lung Cancer | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 37 | 2018-09-11 | 2025-05-09 |
| Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer Nivolumab, 177Lu-DOTA0-Tyr3-Octreotate - Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage | Phase 1 / Phase 2 | Completed | Georgetown University | 9 | 2017-11-20 | 2021-03-16 |
| Phase Ib/II Study of Chiauranib in Patients With Small Cell Lung Cancer Chiauranib - Small Cell Lung Cancer | Phase 1 | Completed | Chipscreen Biosciences, Ltd. | 48 | 2017-11-09 | 2023-08-30 |
| Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors. Tinostamustine 60mg/m2 over 30min, Tinostamustine 80mg/m2 over 30min, Tinostamustine 100mg/m2 over 30min - Small Cell Lung Cancer, Soft Tissue Sarcoma | Phase 1 / Phase 2 | Completed | Mundipharma Research Limited | 71 | 2017-11-08 | 2024-10-21 |
| A Study of PLX2853 in Advanced Malignancies. PLX2853 - Small Cell Lung Cancer, Uveal Melanoma | Phase 1 | Completed | Opna Bio LLC | 49 | 2017-09-12 | 2022-07-25 |
Showing 20 of 50. Sign in to see all of them.
Small Cell Lung Carcinoma (50) · Carcinoma, Non-Small-Cell Lung (14) · Neoplasms (9) · Ovarian Neoplasms (9) · Breast Neoplasms (8) · Triple Negative Breast Neoplasms (7) · Carcinoma, Renal Cell (6) · Pancreatic Neoplasms (6) · Melanoma (5) · Uterine Cervical Neoplasms (5) · Carcinoma, Hepatocellular (4) · Head and Neck Neoplasms (4) · Lung Neoplasms (4) · Lymphoma, Non-Hodgkin (4) · Multiple Myeloma (4)
Bronchial Neoplasms (50) · Carcinoma, Bronchogenic (50) · Lung Diseases (50) · Neoplasms by Site (50) · Respiratory Tract Diseases (50) · Respiratory Tract Neoplasms (50) · Thoracic Neoplasms (49) · Lung Neoplasms (46) · Neoplasms (41) · Neoplasms by Histologic Type (17) · Genital Diseases (14) · Urogenital Diseases (14) · Urogenital Neoplasms (14) · Endocrine Gland Neoplasms (13) · Endocrine System Diseases (13)
Etoposide (7) · Carboplatin (5) · Cisplatin (4) · Nivolumab (4) · Topotecan (4) · Ipilimumab (3) · Temozolomide (3) · pembrolizumab (3) · Bendamustine Hydrochloride (2) · Dexamethasone (2) · Gemcitabine (2) · Injections (2) · Paclitaxel (2) · trilaciclib (2) · 130-nm albumin-bound paclitaxel (1)
AbbVie (4) · Bristol-Myers Squibb (3) · Amgen (2) · G1 Therapeutics, Inc. (2) · Hoffmann-La Roche (2) · Jiangsu HengRui Medicine Co., Ltd. (2) · National Cancer Institute (NCI) (2) · AbbVie (prior sponsor, Abbott) (1) · Advenchen Laboratories Nanjing Ltd. (1) · Alaunos Therapeutics (1) · Ascenta Therapeutics (1) · Ascentage Pharma Group Inc. (1) · AstraZeneca (1) · Celgene (1) · Centre René Gauducheau (1)
United States (38) · Spain (9) · Japan (7) · Canada (6) · France (6) · South Korea (6) · Belgium (5) · China (5) · Australia (3) · Netherlands (3) · Taiwan (3) · Denmark (2) · Hungary (2) · Italy (2) · Poland (2)
Allen Lee Cohn, MD (1) · Ana Oaknin, MD (1) · Anish Thomas, M.D. (1) · Bradford A. Perez, M.D. (1) · Cesare Gridelli, M.D. (1) · Chet Bohac, MD, MSc (1) · Christopher Kelsey, MD (1) · Chul Kim, MD (1)
PMID 33595690, PMID 34405547, PMID 34408488, PMID 21282543, PMID 21633906, PMID 22031232, PMID 24879333, PMID 25225420, PMID 25728526, PMID 25915780, PMID 25944802, PMID 26106073, PMID 26541586, PMID 26640780, PMID 27000274, PMID 28291390, PMID 28548889, PMID 28558150, PMID 28679770, PMID 29290251, PMID 30327308, PMID 30786188, PMID 31189049, PMID 31420359, PMID 31504118, PMID 32616557, PMID 32946924, PMID 33002543, PMID 33004541, PMID 33123968, PMID 33741442, PMID 33934351, PMID 34114913, PMID 34607222, PMID 35387780, PMID 35642431, PMID 35728046, PMID 35842567, PMID 38300341, PMID 39113428, PMID 40036983, PMID 40657894, PMID 42820295
2016 (4), 2014 (2), 2008 (1), 2018 (1), 2019 (1), 2023 (1)